骨形成不全症治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Osteogenesis Imperfecta - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0777
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Osteogenesis Imperfecta – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Osteogenesis Imperfecta – Pipeline Review, H1 2020, provides an overview of the Osteogenesis Imperfecta (Genetic Disorders) pipeline landscape.

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bones that break easily, often from little or no apparent cause. This disease is caused by a defect, or flaw, in the gene that produces type 1 collagen, a protein used to create bone. Symptoms include bone deformities, multiple broken bones, loose joints, weak teeth, heart defects and respiratory problems. Treatment includes bisphosphonates and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Osteogenesis Imperfecta – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively.

Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteogenesis Imperfecta (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteogenesis Imperfecta (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteogenesis Imperfecta (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteogenesis Imperfecta – Overview
Osteogenesis Imperfecta – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Osteogenesis Imperfecta – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteogenesis Imperfecta – Companies Involved in Therapeutics Development
Amgen Inc
Aptacure Therapeutics Ltd
Bone Therapeutics SA
Genzyme Corp
Mereo Biopharma Group Plc
Mesentech Inc
Osteogenesis Imperfecta – Drug Profiles
ALLOB – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aptamer to Inhibit Sclerostin for Osteogenesis Imperfecta – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setrusumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize EP4 Receptor for Osteoporosis and Osteogenesis Imperfecta – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Osteogenesis Imperfecta – Dormant Projects
Osteogenesis Imperfecta – Discontinued Products
Osteogenesis Imperfecta – Product Development Milestones
Featured News & Press Releases
Jan 14, 2020: Mereo BioPharma announces additional positive data from phase 2b ASTEROID study of setrusumab in adults with osteogenesis imperfecta and provides update on regulatory progress
Nov 11, 2019: Mereo Biopharma’s Setrusumab demonstrates dose-dependent bone building and trend in fracture reduction in phase 2b ASTEROID study in adults with osteogenesis imperfecta
Oct 23, 2019: HKBU drug the first in Hong Kong to be granted orphan drug designation by the US FDA
Sep 04, 2019: Mereo BioPharma announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting
Jun 03, 2019: Mereo reports positive data of setrusumab in Phase IIb open label arm
Oct 15, 2018: Completion of patient enrolment in phase 2b study of BPS-804 for the treatment of osteogenesis imperfecta
Nov 13, 2017: Mereo Receives EMA PRIME Designation for BPS-804 to Treat Osteogenesis Imperfecta
May 04, 2017: Initiation of BPS-804 potentially pivotal Phase 2b study in patients with osteogenesis imperfecta, an orphan disease
Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme
Jun 30, 2016: Mereo’s BPS-804 granted EU Orphan Drug status for Osteogenesis Imperfecta
Mar 02, 2016: Mereo BPS-804 granted U.S. orphan drug status for osteogenesis imperfecta
Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Osteogenesis Imperfecta, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Osteogenesis Imperfecta - Pipeline by Amgen Inc, H1 2020
Osteogenesis Imperfecta - Pipeline by Aptacure Therapeutics Ltd, H1 2020
Osteogenesis Imperfecta - Pipeline by Bone Therapeutics SA, H1 2020
Osteogenesis Imperfecta - Pipeline by Genzyme Corp, H1 2020
Osteogenesis Imperfecta - Pipeline by Mereo Biopharma Group Plc, H1 2020
Osteogenesis Imperfecta - Pipeline by Mesentech Inc, H1 2020
Osteogenesis Imperfecta - Dormant Projects, H1 2020
Osteogenesis Imperfecta - Discontinued Products, H1 2020

【掲載企業】

Amgen Inc
Aptacure Therapeutics Ltd
Bone Therapeutics SA
Genzyme Corp
Mereo Biopharma Group Plc
Mesentech Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[骨形成不全症治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆